Oncology MRI


Could an Emerging AI Platform Supplant Traditional MRI for Assessing Prostate Cancer?

December 07, 2022

The Food and Drug Administration has granted 510(k) clearance to iQuest (Avenda Health), an artificial intelligence (AI) platform that combines findings from magnetic resonance imaging (MRI), pathology reports and biopsy results to facilitate three-dimensional mapping of prostate cancer.

What BI-RADS Changes Are on the Way for Breast MRI Reporting?

December 02, 2022

In a recent lecture at the Radiological Society of North America (RSNA) conference, Wendy DeMartini, MD, discussed a variety of preliminary proposed changes to the Breast Imaging Reporting and Data System (BI-RADS) for breast magnetic resonance imaging (MRI) examinations.

Can MRI-Based Prostate Cancer Screening be a Viable Alternative to PSA Testing?

December 01, 2022

In what may be the first study to assess the effectiveness of biparametric magnetic resonance imaging (MRI) for prostate cancer screening in a large cohort, researchers found that MRI screening had a significantly lower false positive rate and significantly higher positive predictive values (PPVs) than prostate-specific antigen (PSA)-based screening.

Enhancing MRI Efficiency and Quality: Can the New SIGNA Experience Have an Impact?

November 29, 2022

Recently launched at the Radiological Society of North America (RSNA) conference, the SIGNA Experience reportedly features synergistic technologies and artificial intelligence (AI) advances that help improve the efficiency and quality of magnetic resonance imaging.

Current Insights on AI, Breast Cancer Screening and the FDA

November 08, 2022

In a recently published article, researchers from Yale University discuss the pros and cons of current FDA regulations as they apply to the clearance and use of adjunctive artificial intelligence (AI) software with conventional breast cancer screening modalities such as mammography.

Radiotherapy for Prostate Cancer: Study Says MRI Guidance Significantly Reduces GU and GI Toxicities

October 28, 2022

For patients undergoing stereotactic body radiotherapy (SBRT) for prostate cancer, the acute genitourinary (GU) toxicity rate associated with the procedure was 19 percent lower with magnetic resonance imaging (MRI) guidance in comparison to computed tomography (CT) guidance, according to new research presented recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting.